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Abstract
Mass spectrometry is an analytical technique for the characterization of biological samples and is increasingly used
in omics studies because of its targeted, nontargeted, and high throughput abilities. However, due to the large
datasets generated, it requires informatics approaches such as machine learning techniques to analyze and interpret
relevant data. Machine learning can be applied to MS-derived proteomics data in two ways. First, directly to mass
spectral peaks and second, to proteins identified by sequence database searching, although relative protein quanti-
fication is required for the latter. Machine learning has been applied to mass spectrometry data from different
biological disciplines, particularly for various cancers. The aims of such investigations have been to identify bio-
markers and to aid in diagnosis, prognosis, and treatment of specific diseases. This review describes how machine
learning has been applied to proteomics tandemmass spectrometry data. This includes how it can be used to identify
proteins suitable for use as biomarkers of disease and for classification of samples into disease or treatment groups,
which may be applicable for diagnostics. It also includes the challenges faced by such investigations, such as pre-
diction of proteins present, protein quantification, planning for the use of machine learning, and small sample sizes.
Introduction
The comparison of samples belonging to differentphysiological states is vital in the search for putative
biomarkers, and proteomics provides suitable methods for
this purpose, through the quantitation of proteins. Proteomics
provides some advantages over transcriptomics as it can both
be used in cell-free biological fluids, such as serum, urine, and
synovial fluid, and provide further knowledge such as
through post-translational modifications. Quantitative meth-
ods, to identify the amounts of proteins, can also be applied,
which can be an advantage over quantifying levels of gene
expression, depending on the purpose of the study, as gene
expression does not necessarily correlate with protein levels.
However, the value of this technology is dependent on the
quality of the analysis methods used to process the generated
data (Bantscheff et al., 2007, 2012).
Machine learning techniques have been utilized broadly
to analyze data from many areas of biology; in particular,
variousmachine learningmethods have been applied to data
generated by the analytical techniques of transcriptomics
and metabolomics for classification of unknown samples
and identification of genes relevant to the disease state.
Similar methods are now being applied to the field of
proteomics and, more specifically, the analysis of data gen-
erated from tandem mass spectrometry (Sun and Markey,
2011).
There are numerous technologies used to extract quanti-
tative protein information from biological samples. These
techniques cover a broad spectrum of approaches, balancing
throughput (one/many proteins at a time) and quality of the
extracted data.
Commonly used techniques include two-dimensional
gel electrophoresis, enzyme-linked immunosorbent assays
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(ELISAs), protein arrays, affinity separation, and mass
spectrometry-based technologies (Ray et al., 2011; Schiess
et al., 2009).
A number of these methods, including gels and ELISAs,
are limited in the number of proteins they can analyze be-
cause of time requirements. They also require specific pro-
teins of interest to be chosen when designing the study and
suitable cross-reactive antibodies to be available; this can be
challenging for non-model organisms. In comparison, mass
spectrometry (MS) techniques can be used as a high-
through-put discovery based method; lists of proteins can be
identified from samples that are analyzed (Perkins et al.,
1999). This means that tandem mass spectrometry can be
used to find proteins that may not have previously been
considered, provided the proteins can be found within pro-
tein sequence databases. A combination of multiple pro-
teomics methods can also be utilized to form an effective
analysis pipeline. Ray et al. (2011) showed that MS, in vari-
ous guises, has been pivotal to biomarker discovery for a
range of different diseases. This review will discuss the ap-
plications of machine learning for analysis of proteomicmass
spectrometry data and the challenges involved. MS-specific
challenges, including the identification of proteins using
sequence database searching software and protein quanti-
tation or pre-processing for peak analysis, will be covered.
As will machine learning-specific considerations, such as the
small numbers of samples that can often result from an MS
investigation, and the types of machine learning most suited
for the required task, either sample classification or bio-
marker identification. A survey of articles involving the
combination of mass spectrometry and machine learning
will be followed by a brief discussion of post-machine
learning analysis, including literature mining and pathway
analysis. An overview of the areas to be covered in this re-
view is provided in Figure 1.
Proteomic Mass Spectrometry Workflow
Overview
MS is used to measure the mass-to-charge ratio (m/z) of
molecules, however, prior to MS taking place, the molecules
must first be electrically charged and changed to gas phase;
this is due to the electromagnetic fields involved in the mass
analyzer stage of MS (Walther and Mann, 2010). Electro-
spray ionization (ESI) (Fenn et al., 1989) is a commonmethod
used for the ionization of molecules, however other methods
are becoming increasingly popular, including matrix-as-
sisted laser desorption/ionization (MALDI), from which
surface-enhanced laser desorption ionization (SELDI) has
been developed (Domon and Aebersold, 2006; Yates et al.,
2009). ESI has been further developed to form nano-ESI, a
technique that offers a number of benefits including smaller
analyte requirements, greater tolerance of contaminants, and
higher sensitivity to hydrophilic compounds (Schmidt et al.,
2003; Wilm and Mann, 1994). After molecules have been
transformed to gas phase, their m/z ratios are measured by
their movement through an electric or magnetic field, this
occurs in a mass analyzer. There are a number of different
types of mass analyzer, including quadrupole, time-of-flight
(TOF), ion trap, and Fourier Transform (FT). These systems
each have different strengths and weaknesses, such as the
range of m/z values that can be detected and the mass
spectrometric resolution. Some mass analyzers can also be
used in combination, such as Quadrupole-TOF, for identi-
fying more complex molecules. Once measured, the m/z
values are visualized as mass spectra, which describe the
molecules present through peaks at the relevant m/z values
(Aebersold and Mann, 2003).
In proteomics, the most widely used method for protein
identification using MS is known as the ‘‘bottom-up’’ ap-
proach. Using this approach, the molecules measured are
peptides, which are generated by the enzymatic digestion of
the peptides in a sample (McLafferty et al., 2007). This ap-
proach determines the m/z values for the peptides present,
collision-induced dissociation (CID) is then applied during
which peptides are fragmented by collisionwith an inert gas,
such as helium (Walther and Mann, 2010). The final stage of
MS includes a detector, which is used to record and amplify
the amount of ions at the different m/z values. The m/z
values are then visualized using mass spectra. The resulting
spectra from the fragmented peptides, known as tandemMS
spectra (MS/MS), are generated wherein the peaks describe
the amino acids present in the peptides (Aebersold and
Mann, 2003). Yet, this only provides the identifications of the
peptides that are present in the sample after enzymatic di-
gestion occurred and so it is still necessary to work back
from the known peptides to predict which proteins were
originally present in the sample. This process can be
accomplished, from the MS/MS data, by sequence data-
base searching software, such as Mascot (Cottrell, 2011),
this is discussed further in a later section. The ‘‘bottom up’’
approach is in contrast to the ‘‘top-down’’ method, for
which MS is used to directly analyze undigested proteins,
through the ionization and dissociation of the intact proteins
in the mass spectrometer. This approach can be more specific
than ‘‘bottom-up,’’ however, it has greater experimental re-
quirements and requires more complex instruments
(McLafferty et al., 2007) for it to be applicable to a global
scale analysis.
Opportunities and challenges of mass spectrometry
data analysis
The use of mass spectrometry for the discovery of proteins
has opened up a number of opportunities; however, there are
also technical and conceptual challenges that need to be
overcome and these will vary from study to study.
A major role for the identification of proteins using mass
spectrometry is the discovery of biomarkers of disease
(Diamandis, 2004). Biomarkers can be used for a variety of
different purposes. They can be used to determine if a bio-
logical process is taking place. They can also serve as indi-
cators for the diagnosis or prognosis of disease and to
determine the course of progression of a known disease.
Biomarkers can also be used to investigate the efficacy of
treatments and interventions or existing or investigational
drugs (Williams, 2009).
Another opportunity that mass spectrometry provides is
viewing proteins on a network level or in functional path-
ways. Understanding the expression of proteins in a pathway
can provide essential knowledge in the changes involved
during progression of disease as well as identification of po-
tential drug targets (Ashburner et al., 2000; Bassel et al., 2011;
Kanehisa and Goto, 2000; Neilson et al., 2011).
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MS is not always suitable due to some limitations; it is
often impractical to produce large numbers of samples due
to time and financial constraints. Furthermore, a high-
through-put approach is not always required (Aebersold
and Mann, 2003). There is also some difficulty in finding
proteins of interest if they are at low abundance, when
compared to other proteins within the sample, which is often
the case for proteins that may be suitable as disease bio-
markers (Horgan and Kenny, 2011; Ray et al., 2011). Another
challenge in mass spectrometry proteomics is unambigu-
ously identifying the proteins from the peptides identified,
mainly due to a lack of sequence data for some species (Tan
et al., 2009). Another challenge is the quantification of pro-
teins (Neilson et al., 2011). Methods include both labeled,
such as stable isotope tagged peptides, and computational
label-free techniques. Label quantification techniques are not
always appropriate for certain experimental systems, in
which case label-free methods can be applied (Neilson et al.,
2011). Protein quantitation is discussed further in a later
section.
Mass Spectrometry Data Analysis
Overview
Tandem MS generates large data files containing lists of
many peaks that are used to identify peptides. The im-
plementation of computational methods is necessary for pro-
cessing, to identify proteins that relate to the identified peaks
and to compare samples. Inmost cases,mass spectrometry data
analysis follows one of the paths that are summarized in Figure
2. The first, shown on the left of Figure 2, looks directly at MS
peaks and their intensities (Katajamaa and Oresic, 2005). The
second uses sequence database search engines to identify
which proteins are present (Perkins et al., 1999). The second
FIG. 1. An overview of the topics covered in this review, including the general
work flow required and the major considerations that are necessary before be-
ginning an investigation combining mass spectrometry and machine learning.
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method is also used in conjunction with protein quantification
techniques (Neilson et al., 2011), which can be applied during
preparation of samples beforemass spectrometry, or during the
data analysis phase, in the case of label-free methods.
Various software packages are used at different stages of
the workflow shown in Figure 2. Some frequently used tools
are detailed in Table 1.
Peak picking
In peak picking, the mass spectra produced are analyzed
without actually determining which peptides or proteins are
present, instead peaks with significantly high signal intensities
are considered as possible biomarkers. There are some draw-
backs to thismethod. First, this is not a directmethod for finding
proteins present in a sample, and further analysis is required.
Second, thorough pre-processing of the peak data is essential,
including normalization, peak alignment, and noise reduction
(Katajamaa and Oresic, 2005). Without these pre-processing
steps it is not possible to compare the same peaks in different
samples accurately, and errors generated at this stage will be
transmitted through to further analyses (Roy et al., 2011).
Search engines
During tandem mass spectrometry, peptide masses are
identified that are present in the samples analyzed. These
peptide masses in conjunction with the masses of their frag-
ments are then used to determine which peptides are present
and the proteins to which they relate. Sequence database
searching software, such as Mascot (Perkins et al., 1999), have
been developed to discover which proteins are most likely to
be present. These software work in conjunction with protein
sequence databases, such as UniprotKB ( Jain et al., 2009)
and NCBInr (http://www.ncbi.nlm.nih.gov/), as well as
species-specific databases, including sgn for Tomato (http://
solgenomics.net/) and Tair for Arabidopsis (http://www
.arabidopsis.org/); they assess the peptides present and, by
comparison with the equivalent masses/fragment masses
calculated from known protein sequences found in the asso-
ciated databases, protein identities are predicted. Thismethod
is not completely accurate because of the similarity of some
protein sequences and the small proportion of the overall
protein sequence to which the identified peptides may relate
(Neilson et al., 2011; Perkins et al., 1999). Also, protein iden-
tifications can only be made if they are present in the inter-
rogated database. However, various metrics are reported
alongside proteins to show the probability that the correct
identification has been made (Cottrell, 2011).
Protein quantification
There are two main types of mass spectrometry-based
protein quantitation: labeled and nonlabeled. The former in-
volves added steps during the sample preparation, prior to
mass spectrometry, but can be performed in a variety of ways
(Bantscheff et al., 2012; Neilson et al., 2011). Chemical and
peptide labeling approaches are common, a frequently used
example of this is iTRAQ (Boehm et al., 2007). Other label
quantification methods include those that label proteins
metabolically, for example, stable isotope labeling by amino
acids in cell culture (SILAC) (Ong et al., 2002). Another
method, Selected Reaction Monitoring (SRM), which is used
for targeted quantitation, involves the selection of ions during
the second mass spectrometer phase of MS/MS (Gillette and
Carr, 2013; Lange et al., 2008). Finally, there are methods that
result in absolute protein quantitation, including those that use
stable isotope labeling standards, such as AQUA and Qcon-
CAT (Beynon et al., 2005; Gerber et al., 2003). There are some
reasons why labeled quantitation methods are not always ap-
propriate or possible, including expensive isotope labeling, a
limit on the number of samples that can be analyzed, and an
incompatibility with some sample types. They must be in-
cluded in the design of the experiment and so are only suitable
if quantitation has been planned from the outset. To quantify
proteins without these additions to themethodology, label-free
quantification techniques are available (Neilson et al., 2011).
There are two types of label-free quantification methods:
measurement of signal intensity and spectral counting. The
first method uses area under the curve of spectral peaks (AUC)
to compare amounts of peptides present in samples. The sec-
ondmethod sums upallMS/MS spectra seen for peptides from
a single protein (Neilson et al., 2011). There are many label-free
quantitation software available, including both commercial
and open source. Examples of freely available AUC methods
include MSInspect (Bellew et al., 2006) and MSQuant (Schulze
andMann, 2004). A basic method of spectral counting, emPAI,
is automatically included byMascotwhen identifying proteins.
Other examples of spectral counting software available for
quantification of proteins include PepC (Heinecke et al., 2010)
and APEX, which can be used for label-free quantitation (Lu
et al., 2007; Vogel and Marcotte, 2008).
FIG. 2. Proteomics mass spectrometry data analysis work-
flow. The workflow diverges into two sections; the first in-
volves peak picking and application of machine learning
directly on mass spectral peaks. This is in comparison to the
second section, which involves quantification of proteins,
either labeled or label-free, followed by machine learning.
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Whilst computational label-free methods can be simpler to
implement because of their reduced laboratory requirements,
the samples being analyzed only come together in silico (Neil-
son et al., 2011). This allows for more variation to occur during
sample preparation, which can be partially avoided using la-
beled methods because samples, once labeled, are brought to-
gether at as early a stage in the workflow as possible.
Quantitative methods provide numerical values related to
the proteins that are discovered by mass spectrometry; this is
advantageous when machine learning techniques are to be ap-
plied to identify biomarkers or classify samples. Whilst there are
other experimental proteomic techniques that can be used to
quantify proteins, such as Western blotting (Voshol et al., 2009;
Wilm, 2009), which are discussed in a later section, these meth-
ods are not comparable with the level of throughput that can be
achieved using mass spectrometry (Bantscheff et al., 2007).
Machine Learning
Machine learning involves generating programs that im-
prove their performance when undertaking a certain task,
based on its experience. Machine learning can take various
forms, which can be applied when each sample has been an-
notated with a quantitative label (Mitchell, 1997; Yang, 2010);
here we will be focusing on the application of supervised ma-
chine learning to mass spectrometry data. Supervised machine
learning involves training a model based on data samples that
have known class labels associated with them. This is in con-
trast with unsupervised classification, or clustering, where no
samples have associated class labels, and instead samples with
similar attribute profiles are grouped together.
This section introduces the concept of supervised classifi-
cation and six types of machine learners: Bayesian classifiers,
Rule-based learners, Decision trees, Random Forest, Support
Vector Machines, and Artificial Neural Networks. These
methods are also summarized and compared in Table 2. This
is followed by a brief discussion of feature selection, which
involved the selection of significant attributes for reduction of
datasets, with the aim to increase the accuracy of classification
models which are then applied to the features selected. Fi-
nally, this section discusses the evaluation of classification
models, to determine how well they classify datasets. This
Table 1. Selection of Software Tools for the Analysis of Mass Spectrometry Data
Software Use Open source URL Reference
Processing of raw peak data
mzMine Peak detection, labeling,
deisotoping.
Y http://mzmine.sourceforge.net/ (Katajamaa et al., 2006)
Sequence database search engines
Mascot Determines proteins
present in a sample.
Also includes emPAI for
protein quantification
N http://www.matrixscience.com/ (Perkins et al., 1999)
Sequest Determines proteins
present in a sample.
N http://fields.scripps.edu/sequest/ (Link et al., 1999)
X!Tandem Determines proteins
present in a sample.
Y http://www.thegpm.org/tandem/ (Craig and Beavis, 2004)
Label-free quantification of proteins
emPAI Label free (included in
Mascot results)
Y http://www.matrixscience.com/
help/quant_empai_help.html
(Ishihama et al., 2005)
PepC Label free Y http://sashimi.svn.
sourceforge.net/viewvc/
sashimi/trunk/trans_
proteomic_pipeline/
src/Quantitation/Pepc/
(Heinecke et al., 2010)
APEX Label free, including
absolute quantitation
Y http://pfgrc.jcvi.org/index.php/
bioinformatics/apex.html
(Vogel and Marcotte,
2008)
Feature selection/machine learning
WEKA Includes many methods
for both feature selection
and classification
Y http://www.cs.waikato.ac.nz/ml/
weka/
(Witten et al., 2011)
Multiple functions
R packages There are many different
packages available
for analysis of MS
data using
R, including
‘xcms’ and
‘MassSpecWavelet’
for processing
of mass spectral data,
along with other
Bioconductor packages.
Y http://www.r-project.org/
http://bioconductor.org/packages/
release/bioc/html/xcms.html
http://bioconductor.org/packages/
release/bioc/vignettes/
MassSpecWavelet/inst/doc/
MassSpecWavelet.pdf
(Du et al., 2007;
Gentleman et al.,
2004; Smith et al.,
2006)
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includes simply dividing the data into training and test sets or
using a form of cross-validation. Text box 1 describes some
terms associated with sample classification.
Classification methods
Supervised machine learning can be used for classification;
a model is built from training data, which includes class labels
for each sample, by assessing values of the attributes. The
model is then used to determine the class of each sample in a
dataset, which has no such labels, known as the test set
(Kotsiantis, 2007; Larran˜aga et al., 2006). Classes can be dif-
ferent phenotypes, such as disease groups or treatments. At-
tributes can be the peak mass-to-charge ratio values or
identified proteins. Classification can be used, for example, in
diagnosing diseases, as the model should determine between
healthy and diseased samples. It is also possible to consider
the specific attributes as biomarkers for the defined classes
(Abeel et al., 2010; Saeys et al., 2008).
Bayesian classifiers. Bayesian classifiers are statistical
methods based on Bayes theorem (Casella and Berger, 2002).
Naive Bayes ( John and Langley, 1995) is the simplest of this
group; it works by estimating the probability that each sample
input belongs to each of the classes. It is said to be ‘naı¨ve’
because it assumes that attributes are independent of each
other. Despite this assumption, Naı¨ve Bayes has shown to be a
very competent machine learning method across many ap-
plication domains and has excellent scalability.
Rule-based learners. This group of learners includES
BioHEL (Bacardit et al., 2009) and JRip (Cohen, 1995). Their
purpose is to automatically generate sets of human-readable
rules (e.g., ‘IF Attribute A >2 AND Attribute B <4, THEN
Class =One’) that explain why a certain group of samples
belongs to a class (e.g., treatment group) of a problem
(Fu¨rnkranz, 1999). Rule learning is a very broad family of
methods. Their differences depend (a) on the type of rule sets
they generate (e.g., ordered/disordered rule sets, crisp/fuzzy
rules) and (b) on how to build the rules (e.g., using a con-
structivist heuristic/using a global search method such as a
genetic algorithm), and the rule sets (e.g., generating at once
all the rules in a rule set/constructing a rule set iteratively).
Decision trees. Decision trees aremachine learningmodels
that structure the knowledge used to discriminate between ex-
amples in a tree-like structure. Figure 3 shows a simple decision
tree, which divides a dataset into its three classes based on the
values of two attributes. Simple decision trees are very easy to
read to understand how the classification has been built and
which attributes it uses. New instances are classified by fol-
lowing the tree along the relevant branches, depending on the
attributes of the sample. Methods, such as C4.5, start with an
empty tree and iteratively split the data, creating branches of the
tree, until they decide to assign all examples of a branch to a
specific class, creating a leaf of the tree, based on a certain criteria
(e.g., all examples in the node belong to the same class/the error
in the branch of the tree is small enough (Quinlan, 1993).
Random Forest. The Random Forest method builds on
that of decision trees, wherein multiple trees are built from the
training data. Each tree has only access to a randomly sam-
pled subset of the attributes of the problem. Then, when
predicting the class of the test samples, each individual tree
predicts a class and the majority class predicted among the
trees is used (Breiman, 2001).
Support Vector Machines. Support Vector Machines
(SVMs), shown in Figure 4, are a class ofmachine learning that
base their prediction in the concept of linear separability be-
tween classes. The characteristics that specifically define
SVMs are (a) the criteria they use to define the optimal linear
Table 2. Comparison of Some Commonly Used Machine Learning Methods
Method Advantages and disadvantages
Speed of learning
(considering size
of dataset)
Ease of
interpretation
Naı¨ve Bayes Fast and easy to implement. This method is suitable for
datasets with missing values. The main disadvantage
is it assumes attributes are independent of each other.
1 4
Decision trees The output from decision trees can be easily interpreted,
but it does depend on the algorithm used and the
complexity of the tree generated. It is also well suited
to datasets with missing values.
2 = 1
Random Forest This method is efficient on large datasets and can handle
large numbers of attributes, however it is not very
sensitive to outliers.
4 3
Rule-based classifiers The rules generated are easily readable, and is suitable for
identification of putative biomarkers, however there is
a possibility of over-fitting.
3 = 1
Support vector
machines (SVMs)
SVMs uses kernels to learn complex functions, however they
are very slow and there are multiple parameters to be
chosen by the user.
= 5 = 5
Artificial neural
networks (ANNs)
ANNs use a multilayer perceptron to learn complex functions.
The output of ANNs are not able to be read and the
training of the model can be very slow.
= 5 = 5
The speed of learning and ease of interpretation rows rank the methods 1 to 6, with 1 being the best (Kotsiantis, 2007).
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classifier based on the concept of separation margin maxi-
mization, (b) the identification of the so-called support vec-
tors, the minimal set of training instances that are necessary to
define the optimal linear classifier; because they lay at the
edges of themargin, and (c) the use of kernels to transform the
original set of variables into a higher order non-linear space in
which the linear separability happens. The Sequential Mini-
mal Optimization (SMO) is one of the most popular SVM
algorithms (Platt, 1999).
Artificial Neural Networks. Artificial Neural Networks
(ANNs) are inspired by the workings of the brain. ANNs are
composed of a collection of computational elements (neurons)
that are connected between themusing a very broad variety of
interconnectivity patterns. The connections of a neuron de-
termine whether it becomes activated, based on the signal
they receive. Generally each neuron is a variant of a linear
classifiers, but the inclusion of multiple neurons and layers
result in the construction of sophisticated nonlinear classifiers
that allow for their application to complex problems (Dayhoff
and DeLeo, 2001; Mitchell, 1997). A representation of ANNs is
shown in Figure 5.
Feature selection methods
Feature selection methods have the primary role of select-
ing significant attributes, through removal of redundant or
irrelevant attributes, and therefore can also be used for bio-
marker identification. These methods are applied to pro-
teomics MS data to identify proteins, which vary significantly
between treatments or disease groups, either individually or
in combination with others, and therefore could be potential
biomarkers (Abeel et al., 2010).
Feature selection methods can be used prior to classifi-
cation techniques, as pre-processing, to reduce the size of a
dataset by selecting a subset of attributes, on which a
learner is then applied (Saeys et al., 2008). This can involve
removing redundant, irrelevant, or noisy data ( John et al.,
1994; Kohavi and John, 1997). Feature selection can be used
to reduce the number of attributes because redundant data
have been shown to reduce the accuracy of classifiers. Some
classifiers, such as decision trees, are affected more by ir-
relevant data, compared to, for example, Bayesian classi-
fiers ( John, 1997).
Many feature selection methods are based on machine
learning techniques that have already been discussed, such as
Naı¨ve Bayes (Duda, 2001) and support vector machines
(Guyon and Elisseeff, 2003; Weston et al., 2003).
Validation procedures for machine learning methods
Evaluation of classificationmodels is essential to determine
their ability and accuracy; ideally this would be performed by
producing the model on a training set and testing it on an
independent test set. This is not always possible when the
number of samples is limited, which is often the case when
working with proteomics data, because of limitations in time
and cost of producing many repeats of samples. When an in-
dependent testing dataset is not possible, cross-validation can
be used, as it splits up a single dataset into training and test sets.
FIG. 3. A simplified Decision Tree that divides data into its three classes, based on two
attributes.
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Using 10-fold cross validation, the dataset is split up ten times,
producing ten training sets each consisting of 90% of the data
and ten test sets containing the remaining 10%. There are also
other variations of cross-validation; another commonly used
method is leave-one-out cross-validation where only one
sample is used for the test set and there are training and test set
combinations equivalent in number to the number of samples
available (Ambroise and McLachlan, 2002; Kohavi, 1995).
Whilst cross-validation is useful for analyzing small datasets it
does have disadvantages, the main one being over-fitting. As a
FIG. 4. A graphical representation of Support Vector Machines and the linear division of two
classes.
FIG. 5. A representation of Artificial Neural Networks and the layers involved in the gen-
eration of a model.
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result models may appear to perform better when tested using
cross-validation than when tested on an independent dataset, al-
though some classification algorithms are less prone to over-fit-
ting thanothers.Therefore largerdatasetswouldbemoresuitable,
becausecross-validationwouldnotbeneededtogenerate training
and test sets (Kohavi, 1995; Varma and Simon, 2006).
Machine learning has been used to classify samples across a
variety of diseases (Larran˜aga et al., 2006). Table 3 summa-
rizes eleven investigations that reported the use of machine
learning techniques for the classification of samples, after
analysis with MS. This includes application to both peak
data and quantified proteins. The articles were identified by
querying both PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and Google Scholar (http://scholar.google.com/)
for the search terms ‘machine learning’ and ‘proteomic mass
spectrometry’, optionally followed by the term ‘biomarkers’.
The search was done first without the term ‘biomarkers’ so
that articles applying machine learning to proteomics data
which did not include the identification of biomarkers could
also be retrieved (searched January 2013).
Classification accuracies are reported with the percentage
of samples correctly assigned to their relevant classes; this can
be generated either using a test dataset or cross-validation.
From the investigations surveyed, cross-validation was a
popular method for generating training and test sets, as it
particularly useful when there is a limit on the number of
samples it is possible to produce. There were a range of cross-
validation techniques used; the most popular was leave-one-
out cross-validation, but others, including 10-fold and 3-fold
were used. The alternative is to split the dataset up into
training and test sets. This was performed for the datasets
with larger numbers of samples. One investigation compared
both cross-validation and splitting up the dataset and found
the best classification accuracy, for their dataset, using leave-
one-out cross-validation (Guan et al., 2009). However, this
result is specific to this dataset and so it would be useful to
perform similar analyses on other datasets, as not all datasets
would give the same results. As a result of the majority of
studies using cross-validation, many reported a further re-
quirementwould be to repeat their analysis on larger datasets.
Table 3 includes information on the percentage accuracy, and
the machine learning method used. It is also necessary to
consider how the data are split up into separate classes.
Bloeman et al. (2011) included both diagnosed and non-
diagnosed asthma samples in their dataset. With these sam-
ples considered in one class, as classification accuracy of 100%
was achieved, however when they were split into two dif-
ferent classes, the accuracy of the model lowered to 73%.
Table 3 shows that a variety of machine learning methods
were used for the classification of samples, with SVMs themost
popular choice, being used in four of the eleven investigations
surveyed. These analyses included the use of both proprietary
and open source software, many applying machine learning to
actual peak data, rather than quantified proteins. One article
(Guan et al., 2009) provides a good example of increasing clas-
sification accuracy by combining a classifier with a feature se-
lectionmethod.Alone, the best SVMclassifier evaluatedon that
dataset achieved an accuracy of 83.3% when assessed with
leave-one-out cross validation, however this was increased to
97.2% when combined with an SVM-based feature selection
method. However, it is impossible to compare accuracies
achieved across different datasets because the datasets result in
problems of varying difficulties. It can be useful to compare
accuracies of different methods used for the same dataset, for
example where different parameters for SVMs were tested, as
well as the comparison of various feature selection techniques,
to identifywhich combination of feature selection and classifier
work best together (Willingale et al., 2006).
Biomarker discovery
Machine learning can also be useful in determining
which proteins, from MS data, could be used as biomarkers
to differentiate between samples of different classes (Saeys
et al., 2008). Table 3 also includes information from inves-
tigations on the application of machine learning on mass
spectrometry data for the identification of the most suitable
biomarkers, based on factors such as the ability to test for
proteins in a clinical setting; this includes both identified
proteins and mass spectral peaks as biomarkers. Further
analysis, following identification of peptides or proteins as
putative biomarkers, are then required, as it may be that
the proteins identified would not actually be suitable for
use as biomarkers. For example, body fluids such as urine
and serum (blood) are regarded as being most suitable
fluids to search for biomarkers because they are easier to
obtain for assessment purposes during diagnostic tests and
treatments. Also, blood is pumped around the body by the
circulatory system and bathes cells, tissues, and organs,
thus carrying putative protein biomarkers around the body
before being processed by the liver and filtered by the
kidneys into urine (Pang et al., 2002; Veenstra, 2007).
Table 3 shows that the number of possible biomarkers
identified varies greatly between studies, due to differing
complexities of data, for example, Ratcliffe et al. (2009) iden-
tified only two m/z values as biomarkers, and Ralhan et al.
(2008) formed a panel of three biomarkers. This is in com-
parison to Guan et al. (2009) and Oh et al. (2009) who iden-
tified 38 and 26 putative biomarkers, respectively. Some
found biomarkers that had previously been identified; this is
both useful as support for the previous investigations, and as
some validation to the methods being newly applied to the
area. Other investigations identified biomarkers that work
specifically well together and so formed panels of markers. In
Fan and Chen (2009), different panels of biomarkers were
compared and those markers that worked best together were
identified. The development of panels of biomarkers is useful
as using multiple biomarkers may reduce false positives as it
removes dependence on individual proteins, and allows
proteins that are detected for different diseases to be useful
(Williams, 2009).
To discriminate between samples, the majority of the
studies applied machine learning to only the peaks from the
mass spectrometry data that correspond to peptides. To fa-
cilitate the development of diagnostic assays and/or inform
the underlying biology at a molecular level, peptide bio-
markers require further investigation.
Literature mining and pathway analysis
Machine learning has been shown to highlight important
peptides/MS peaks, however further analysis is required to
determine to which proteins they relate. In the case of
machine learning applied to quantified proteins, literature
mining is also useful for understanding the biological
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relevance of the proteins identified as potential biomarkers.
It may be important to discover more information about
interacting proteins and pathways in which they have a
role (Hur et al., 2009; Jenssen et al., 2001; Tsuruoka et al.,
2008); by doing this, it can be determined whether the
identified proteins may become useful biomarkers and
which processes would be measured. Pathway analysis can
be used to narrow down, or provide a focus to, the search
for biomarkers by determining which pathways they par-
ticipate in (Lawlor et al., 2009).
Literature mining is also essential in discovering more in-
formation after machine learning has been applied to MS
peaks, however identification of the proteins the peaks relate
to is first required (Oh et al., 2009).
Tools such as Ingenuity Pathway Analysis (http://www
.ingenuity.com) and DAVID (Huang et al., 2008, 2009) can be
used to facilitate literature mining and pathway analysis, or
information can be mined directly using such article databases
as PubMed (http://www.ncbi.nlm.nih.gov/pubmed).
Machine Learning and Other –Omics Technologies
There are many other techniques generating large datasets
from biological samples, for which machine learning ap-
proaches are beneficial. These methods, including tran-
scriptomics, metabolomics, and lipidomics, can also be used
in conjunction with proteomics to gain a broader view of the
biological system under analysis ( Joyce and Palsson, 2006;
Silvestri et al., 2011; Tan et al., 2009).
Other proteomics methods include Western blots, dot-blots,
ELISAs, protein arrays, and antibody arrays. However, these
techniques cannot achieve the same high-throughput as MS/
MS and therefore the data generated would not be suitable for
machine learning and do not require this level of analysis
(Bantscheff et al., 2007; Voshol et al., 2009; Wilm, 2009).
Transcriptomics has historically been dominated by mi-
croarray technologies, but now next generation sequencing is
becoming more popular, due to its greater sensitivity, larger
dynamic range, and advantage of not being limited by
Table 4. Summary Table of Considerations for the Stages of a Proteomics Machine Learning Experiment
Considerations for experimental design
 Is machine learning to be applied to mass spectral peak data or to identified proteins? The former does not require the use
of quantification methods, but further analysis is required after application of machine learning to identify the proteins
related to peaks of interest.
 What is required from machine learning: biomarker identification or unknown sample classification? Whilst all methods
can be used for classification, not all can be used for biomarker identification; the most suitable are those such as rule-based,
which report the proteins used in rules that classify samples.
 What are the limitations on the number of samples produced and therefore what is the most suitable/realistic number of
samples? Large numbers of samples tend to be more suitable for the application of ML and therefore the case is often the
more samples the better. The limitations can come from the number of samples generated for MS analysis as well as time
and financial restraints. The most suitable number of samples is a balance between all these factors, whilst trying to
maximize the sample size.
 Can labeled quantification be included in the protocol, or is label-free more suitable? Labeled quantitation may not be
compatible with the MS technology available and the purchase of reagents and software are usually required, making these
methods not always suitable. Label-free techniques become the only option when the quantitation of proteins and
application of ML is not considered until after MS analysis. Many label-free methods are also open source, giving them a
financial advantage.
 How large is the dataset? This can impact on the choice of evaluation, how the training and test sets are generated and the
choice of machine learning techniques that are applied. Multiple samples within classes are essential, rather than few
samples across many classes. Cross-validation is frequently used for evaluation of classification on datasets that are not
large.
 Is machine learning likely to over-fit the data? Over-fitting can be caused by classifying on small datasets. Some machine
learning techniques are less prone to over-fitting and others have associated methods to reduce it.
Steps required for application of machine learning
1. Quantification of proteins, either by a labeled or label free method.
2. Generate training and test sets: either by cross-validation or, if a large dataset, by splitting it up to train on the majority of
the dataset and test on a small subsection.
3. Pre-processing: feature selection methods. Feature selection is not essential, but can improve the classification accuracy of
learners.
4. Application of machine learning methods. Models built using training sets and the accuracy of classification determined
though application of models to the test set. Software, such as WEKA (Witten et al., 2011) can be used or methods can be
implemented in R (R, http://www.r-project.org/).
5. Comparison of machine learning methods to identify the best method for the dataset.
Post machine learning analysis
Further analysis to be included if information can be extracted from results of machine learning methods (for biomarker
identification), by identifying proteins that were essential for the classification:
 Literature mining
 Pathway analysis
 Generation of interaction networks
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detecting only genes that are present on arrays (Mardis, 2008).
Both microarrays and next generation sequencing have the
high throughput capabilities that MS/MS does, and therefore
are suitable for machine learning (Tan et al., 2009). Yet there
can be large differences in mRNA and the actual abundances
of proteins (Lawlor et al., 2009).
The main techniques used for the study of the metabolome
are MS, preceded by either gas or liquid chromatography and
NMR (Joyce and Palsson, 2006; Tan et al., 2009). Commonly,
large libraries of peaks are used to identify metabolites, such as
lipids, amino acids, and sugars, to match the peaks identified by
MS. Metabolomics can also be considered as a method com-
plementary to proteomics. It may be that the metabolites are
amplified in comparison to the related proteins, and therefore
more likely to be identified by MS/MS (Tan et al., 2009).
Future Research Directions and Priorities
Machine learning has been successfully applied to pro-
teomics data, yet it can still be used for other purposes and
across a wider range of diseases. For example, the investiga-
tions discussed in Table 3 show machine learning has been
used largely on the proteomics of cancers; therefore there are
many other diseases and biological systems which would
benefit from the application of machine learning.
Rule-based learners, as well as being used for classification,
are suitable for the identification of biomarkers, as the attributes
that are used frequently in rules are those that are better at
discriminating between classes. Rule-based machine learning
has also been applied to microarray data to develop gene in-
teraction networks based on genes that are used together in rules
(Bassel et al., 2011; Glaab et al., 2012). This method could be
applied to mass spectrometry data in the same way, generating
networks from groups of proteins that appear together in rules.
There are also other methods that were originally devel-
oped for transcriptomic data, such as gene set analysis (Luo
et al., 2009), that could be modified for application to pro-
teomics. Furthermore, machine learning could be combined
with literature data to include background knowledge, which
is not necessary for machine learning to be applied, but could
improve the data analysis process (McKinney et al., 2006).
Summary
This review discussed the use of machine learning applied
specifically to proteomics data for classification of samples and
identification of biomarkers, althoughmachine learning can be
applied to other omics data. Investigations that involve mul-
tiple types of omics data can also aid in the identification of
biomarkers, for example, investigations into potential bio-
markers in cartilage and chondrocytes are using both tran-
scriptomics and proteomics data (Lewis et al., 2013;Mobasheri,
2012; Williams et al., 2011). Machine learning analysis requires
large datasets and so it is essential to consider the number and
type of samples that will be generated and their suitability for
the application of machine learning.
The applications of machine learning discussed here have
demonstrated that there are many different methods suitable
for both classification of samples and identification of novel
biomarkers. Therefore, to undertake such an investigation
requires the consideration of a number of matters, summa-
rized in Table 4. Various methods should be tested to identify
which is most suitable for the dataset. There is also a necessity
for further biological evaluation of any protein that is identi-
fied frommass spectrometry as a suitable biomarker. This can
be performed using both laboratory-based and computational
methods, as biomarkers not only need to be differentially
expressed, but other factors, such as ease of sourcing the
sample, must be taken into account.
Further analysis of proteins identified as possible biomarkers
is essential. Pathway analysis is used to verify relationships be-
tween proteins found by machine learning. Pathway analysis
can also be used to understand where proteins that have been
identified as possible biomarkers act, for example, if one protein
is upregulated during progression of a disease, does it result in
other proteins being up- or downregulated.
It can also be seen from the investigations surveyed that the
majority of diseases analyzed are cancers and therefore there
are many other areas for these methods to be applied.
Finally, machine learning can be applied to mass spectrom-
etry data to generate networks that indicate protein interactions.
This is a method that has previously been applied to microarray
data, and is also now applicable to proteomics.
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Text Box 1. Sample Classification Definitions
Attribute: used to describe each sample. For proteomics
these can be the MS peak values or proteins themselves.
Attributes can also be referred to as features or variables.
Biomarker: proteins or MS peak values that can be used
individually, or in combination, with others to discrimi-
nate between classes.
Classes: the division of samples into different groups.
When considering proteomics this can be different disease
or treatment groups, alongwith a control class. Class labels
indicate to which class samples belong.
Classification: amodel is built on a training dataset, with
known class labels, to predict the classes of new, non-an-
notated samples.
Cross-validation: a method for assessing the classifica-
tion ability of a model.
Feature selection: process that identifies and removes ir-
relevant or redundant features (e.g., proteins) from a dataset.
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